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Abstract
Attention-deficit/hyperactivity disorder (ADHD) is the most common neurodevelop‐
mental disorder of childhood characterized by the three core symptoms of hyperac‐
tivity, impulsiveness, and sustained inattention. While the etiology of ADHD remains
unknown, several studies suggest ADHD pathophysiology to involve frontal network
abnormality and dysregulation of catecholaminergic and dopaminergic functions.
Stimulants, which are structurally similar to endogenous catecholamines, are the most
commonly prescribed drugs for treatment of ADHD, but are classified as Schedule II
based on the Controlled Substances Act due to high likelihood for diversion and
abuse. Non-stimulant medications, as well as antidepressants, have also been used in
ADHD treatment but have been found to be inferior to stimulant interventions and
to cause intolerable side effects. The search for safer yet effective ADHD treatments
led to a growing interest in natural medicines and a host of other complementary and
alternative treatments for ADHD. While the use of these therapies is well documented,
not much is known about their safety and efficacy. In this chapter, we describe current
evidence-based complementary and alternative therapies for ADHD, focusing on
nutritional and botanical agents, and provide details on the performance of these
agents in clinical trials. Here, we discuss the rationale for the use of natural products
for ADHD, mention the potential mechanisms of action of these treatments, and
highlight safety and efficacy issues associated with the use of these treatments. In
conclusion, we give an exhaustive update on the use of nutritional and botanical
medicines as complementary and alternative ADHD therapies for ADHD, which
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could potentially provide important information on the efficacy and safety of these
types of interventions.
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1. Introduction
Attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder of
childhood, characterized by the three core symptoms of hyperactivity, impulsivity, and
inattention [1]. Diagnosis of ADHD has been on the rise since it was recognized as a specific
disorder in the 1970s. Currently, the worldwide prevalence rate of ADHD is approximately
5%, making it the most common psychiatric disorder among children [2]. In addition, although
most frequently diagnosed during childhood, ADHD may affect an individual throughout life
[3]. Given its serious academic, social, and familial consequences, along with the risk of
incurring comorbid conditions and later substance abuse, it is imperative to develop effica‐
cious treatments for ADHD [4].
2. Treatment of ADHD: An overview
Numerous treatment strategies for ADHD have been implemented over the years. Conven‐
tional treatment usually includes a pharmaceutical and a non-pharmacological intervention
such as behavioral/psychosocial approaches. We describe in the following text some of the
widely used pharmacological and non-pharmacological ADHD treatments as well as safety
and efficacy and issues or limitations associated with the use of these interventions.
2.1. Pharmacological interventions
ADHD has been associated with dysfunctions in catecholaminergic function in the brain [5].
The fact that medications that increase brain catecholamine levels have been shown to alleviate
ADHD symptoms provided solid support for the use of pharmacological treatments for ADHD
[5]. Drugs used in managing ADHD are classified as stimulant and non-stimulant medications.
Stimulant or psychostimulant drugs are the most common pharmacological intervention for
ADHD [6, 7]. These drugs (e.g., methylphenidate and dextroamphetamine) are structurally
similar to endogenous catecholamines. They work by increasing extracellular dopamine and
norepinephrine levels in order to restore the dysregulated neurotransmitter balance in the
brain of ADHD patients [5]. Methylphenidate (Ritalin® or Concerta®) is the most prescribed
and used psychostimulant accounting for around 70% of ADHD patients who are under
stimulant treatment [6, 8, 9].
Non-stimulant medications such as the norepinephrine specific reuptake inhibitor, atomoxe‐
tine, as well as antidepressants such as imipramine, phenelzine, and bupropion have also been
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used in the treatment of ADHD [9, 10]. Similar to psychostimulants, these drugs act by
increasing catecholamine levels in the brain, thus correcting the perceived neurotransmitter
imbalance. However, non-stimulants have been found to be inferior to stimulant drugs on
efficacy endpoints [6, 10].
Although pharmacological interventions generally improve ADHD symptoms for most
children, as many as 20–30% of children either do not respond to these drugs or are unable to
tolerate them due to the wide range of side/adverse effects they may produce [11, 12]. Common
side effects associated with stimulant use are decreased appetite, insomnia, and headache [11].
Other side effects such as motor tics, abdominal pain, irritability, nausea, and fatigue have also
been reported [9, 13]. For this reason, some parents are unwilling to medicate their children
with stimulants due to concerns about the safety and risks associated with the long-term use.
In addition, stimulants also have a high likelihood for diversion and abuse, and are classified
as Schedule II based on the Controlled Substances Act. This is a major concern since ADHD
has also been associated with increased risk of substance use disorder [14].
2.2. Non-pharmacological interventions
A variety of non-pharmacological interventions is available for treating ADHD. These
treatment strategies can either be used alone or in combination with pharmacological therapy
[13]. Behavioral therapy, also known as behavioral modification, is one of the most common,
effective, and accepted non-pharmacological treatment for ADHD. This therapy, which
typically involves reinforcing desired behaviors through rewards and praise and decreasing
problem behaviors by setting limits and consequences, has shown great promise particularly
in youth and adults with ADHD [15, 16]. Another form of behavioral therapy is social skills
training. This is conducted in a group setting where a therapist or a teacher demonstrates
appropriate social behaviors and then encourages patients to repeat and practice those
behaviors [16, 17]. Other potential approaches include memory training through the use of
computer software (Cogmed), electroencephalography biofeedback or neurofeedback,
exercise, yoga, meditation, acupuncture, and green space [12, 18, 19]. As these therapies are
not widely available, only a few patients can benefit from the effects of behavioral therapy.
Despite the fact that these interventions are easy to implement, time demands, the need of a
professional therapist, and participation by family members and teachers also limit the use of
behavioral ADHD treatments.
Over the years, there has been much interest and controversy on the importance of food and
diet and its potential role in ADHD and ADHD symptomatology [20]. Some food items have
been shown to cause or worsen ADHD symptoms in children. The strategy, therefore, is to
identify offensive food items and eliminate these items from the child’s diet in order to prevent
or minimize the occurrence of ADHD symptoms. This can be done by eliminating the partic‐
ular food item (single-food elimination) or multiple food elements that are most commonly
reported to cause ADHD symptoms. Common culprits include sugar, dairy products, junk
foods, food additives, preservative, and others [18, 21]. Another dietary regimen that has been
gaining support is the “oligoantigenic” or “few foods” diet, which entails strict removal of
nearly all foods, except a limited number that have been proven to cause no problems or are
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deemed “hypoallergenic” [18, 19, 21]. However, due to inadequate research on the efficacy of
these regimens, employing dietary modifications to treat ADHD is still controversial. Fur‐
thermore, continued compliance and nutritional imbalances are causes of concern for dietary
treatments.
3. Natural health products for ADHD
3.1. Rationale for the use of natural health products
In view of the safety and efficacy issues of current pharmacological interventions, and the
desire for safer yet effective ADHD treatments, there has been a growing interest in natural
health products (e.g., botanical/herbal medicines, vitamins, and minerals) and other comple‐
mentary and alternative medicines for ADHD [12, 18, 19]. It has been estimated that more than
50% of parents of children with ADHD treat their child using one or more of these products
[22-25]. Despite their growing popularity, physicians are still reluctant to recommend these
products, as they question the efficacy of these treatments. Thus, only a few families disclose
the use of these products to their child’s physician [18, 24, 25]. Research is still underway to
demonstrate the effectiveness of natural products in the treatment of ADHD. In the following
sections, we describe some of the widely used natural medicines for ADHD, discuss the
potential mechanism of action of these agents, and give updates on their performance in recent
clinical research.
3.2. Updates on natural treatments for ADHD: evidence from clinical studies
3.2.1. Botanical agents
Botanical agents or herbal medicines are popular alternative treatment for ADHD, as they
appeal to parents looking for a more “natural” treatment for their child [12, 18]. Certain
botanical agents have shown promise in the treatment of ADHD in light of the findings of
clinical trials [Table 1].
Herb Methods Results Proposed mechanismof action
Safety and
efficacy Reference
Pycnogenol
⋅ Randomized, double-
blind, placebo-
controlled, study.
⋅ 61 children, 6-14 y/o
with ADHD (n=44
pycnogenol vs. n=17
placebo).
Significant
attenuation of
hyperactivity and
improvement of
attention.
Increased production
of nitric oxide that is
involved in the
regulation of
norepinephrine and
dopamine release and
intake.
Mild side effects,
such as a rise in
slowness and
gastric discomfort,
were reported
Trebatická et
al., 2006 [26]
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Herb Methods Results Proposed mechanismof action
Safety and
efficacy Reference
⋅ Pycnogenol (1 mg/kg/
day) or placebo
treatment for 4 weeks.
⋅ Randomized, double-
blind, placebo-
controlled study.
⋅ 61 outpatient
children, 6-14 y/o with
ADHD (n= not
specified Pycnogenol v.
placebo)
⋅ Pycnogenol (1 mg/kg/
day) or placebo
treatment for 4 weeks
Improvement of
attention,
reduction of
oxidative damage
to DNA and
normalization of
the total
antioxidant status.
Potent antioxidant
properties.
No reported
adverse effects.
Chovanová
et al., 2006
[27]
⋅ Randomized, double-
blind, placebo-
controlled, crossover
study.
⋅ 24 adults, 24-53 y/o
with ADHD (n= not
specified Pycnogenol
vs. placebo vs.
methylphenidate)
⋅ Duration of treatment
is 3 weeks
Neither
methylphenidate
nor Pycnogenol
outperformed the
placebo control on
any ADHD rating
scale employed.
Tenenbaum
et al., 2002
[30]
St. John’s Wort
(Hypericum
perforatum)
⋅ Randomized,
placebo-controlled
trial.
⋅ 3 adolescents, 14-16
y/o with ADHD (n=2
St. John’s Wort v. n=1
placebo).
⋅ St. John’s Wort (30
mg/day) or placebo
treatment, for 4 weeks.
Improvement of
hyperactivity,
inattention and
immaturity
symptoms.
Inhibition of serotonin
and norepinephrine
reuptake.
No reported
adverse effects.
Niederhofer
H., 2010 [33]
⋅ Randomized, double-
blind, placebo-
controlled trial.
No significant
improvement in
ADHD symptoms.
Inhibit serotonin and
norepinephrine
reuptake
No reported
adverse effects.
Weber et al.,
2008 [34]
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Herb Methods Results Proposed mechanismof action
Safety and
efficacy Reference
⋅ 56 children, 6-17 y/o
with ADHD (n=27 SJW
v. n=27 placebo).
⋅ H. perforatum (300
mg) or placebo, 3 times
a day for 8 weeks.
Gingko Biloba
⋅ Open clinical pilot
study
⋅ 20 children with
ADHD
⋅ Ginkgo (EGb 761®),
240 mg daily, was
administered for 3 to 5
weeks.
Improvement of
ADHD core
symptoms.
Elevation of brain
electrical activity,
particularly in
contingent negative
variation (CNV)
amplitude.
A very low rate of
mild adverse
effects occurred
during the
observation
period.
Uebel-von
Sanderslebe
n et al., 2014
[36]
⋅ Randomized, double-
blind controlled trial.
⋅ 50 children, 6-14 y/o
with ADHD(n=25
Ginkgo biloba vs. n=25
methylphenidate)
⋅ Gingko biloba (80-120
mg/day) or
methylphenidate (20-30
mg/day), for 16 weeks.
Gingko Biloba was
less effective than
methylphenidate
in the treatment of
ADHD.
Reverse inhibition of
MAO-A and MAO-B.
Lesser side effects
(headache,
insomnia, and loss
of appetite) than
methylphenidate
Salehi et al.,
2010 [35]
Gingko Biloba
and Ginseng
⋅ Open, pilot study.
36 children, 3-17 y/o
with ADHD.
⋅ Combination of
herbal product
containing American
ginseng extract, Panax
quinquefolium (200 mg)
and Gingko Biloba
extract (50 mg), twice a
day (empty stomach)
for 4 weeks.
Improvement in
various attributes
(anxiety, social,
hyperactive-
impulsive) of
ADHD.
Gingko Biloba can
reverse the reduction
of 5-HTIA2 and
noradrenergic
receptors. It also
stimulates synaptic
plasticity, increased
blood glucose
utilization, reduces
lactate and pyruvate,
increases dopamine
and norepinephrine,
and promotes nerve
growth.
Five (14%) subjects
reported adverse
events (more
emotional & more
impulsive, more
hyperactive and
more aggressive,
sweating,
headache,
tiredness), only 2
of which were
considered related
to the study
medication.
Lyon M.R. et
al., 2001 [37]
ADHD - New Directions in Diagnosis and Treatment356
Herb Methods Results Proposed mechanismof action
Safety and
efficacy Reference
Ginseng
⋅ Observational study
⋅ 18 children, 6-14 y/o
with ADHD.
⋅ Korean red ginseng
(1000 mg) twice a day,
for 8 weeks.
Korean red
ginseng improved
inattentiveness in
ADHD children.
Ginseng can boost
dopamine and
norepinephrine levels
in the brain.
Some participants
complained bad
taste and a degree
of repulsive
feeling.
Lee et al.,
2011 [38]
⋅ Randomized, double-
blind, placebo-
controlled clinical trial.
⋅ 70 children, 6-15 y/o
with ADHD (n=33
Korean red ginseng v.
n=37 placebo).
⋅ Korean red ginseng
extract (1000 mg) and
placebo, twice a day for
8 weeks.
Ginseng extract
significantly
improved the
inattention/
hyperactivity
symptoms of
ADHD.
Ginseng can reduce the
production of the
adrenal corticosteroids,
cortisol, and
dehydroepiandrostero
ne (DHEA).
No serious adverse
reactions reported
apart from loose
stool by one
patient from the
Ginseng group.
Ko et al.,
2014 [39]
Valerian
(Valeriana
officinalis)
⋅ Double-blind,
placebo-controlled
pilot study.
⋅ 30 children, 5-11 y/o
with ADHD (n=10
Valeriana officinalis
mother tincture
(VOMT) or n=10 3x
potency of VOMT v.
n=10 placebo, for 3
weeks)
Significant
improvement in
ADHD symptoms
was found from
VOMT or 3x
potency group, in
comparison to
placebo
Valerian’s main active
compound, valerenic
acid, inhibits the
breakdown of GABA in
the central nervous
system, an action
similar to that of
benzodiazepine drugs.
No reported side/
adverse effects.
Razlog et al.,
2011 [40]
Ningdong
granule
⋅ Randomized, double-
blind,
methylphenidate-
controlled trial.
⋅ 72 children, 6-13 y/o
with ADHD (n=36
Ningdong v. n=36
methylphenidate).
⋅ Ningdong (5 mg/kg/
day) vs
methylphenidate (1
Similar to
methylphenidate,
Ningdong granule
ameliorated
ADHD symptoms.
Regulation of
dopaminergic activity
by increasing
homovanillic acid
content of in sera.
Hypersomnia was
reported as
Ningdong
granule’s side
effects.
Methylphenidate
had more side
effects than
Ningdong granule.
Li et al., 2011
[41]
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Herb Methods Results Proposed mechanismof action
Safety and
efficacy Reference
mf/kg/day), for 8
weeks.
Bacopa (Bacopa
monniera)
⋅ Open-label study
⋅ 31 children, 6-12 y/o
with ADHD.
⋅ Standardized Bacopa
monniera extract
(SBME) (225 mg/day),
for 6 months.
SBME significantly
reduced ADHD
symptom; reduced
scores in
restlessness,
impulsiveness,
learning problems,
impulsivity, and
psychiatric
problems.
Bacopa was shown to
increase dopamine
levels in the cortex.
In addition, it also
possesses
neuroprotective,
antioxidant, and
memory-enhancing
effects.
SBME was found
to be safe and
tolerable in
children. Only
mild
gastrointestinal
side effects (e.g.
nausea) were
observed in 3
subjects.
Dave et al.,
2014 [42]
Table 1. Botanical agents for ADHD
3.2.1.1. Pycnogenol® (French maritime pine bark extract)
Pycnogenol® is a standardized extract from the bark of French maritime pine (Pinus pinaster).
This extract was reported to have a rich store of phenolic acids, catechin, taxifolin, and
procyanidins, each with diverse biological effects. A number of studies have suggested that
Pycnogenol® may be beneficial for ADHD and its symptoms. Of note, a double-blind, placebo-
controlled study of 61 children (ages 6–14 years old) found that Pycnogenol® (1mg/kg/day)
ameliorated the symptoms of ADHD including reduced hyperactivity, increased attention,
and improved visual-motor coordination [26]. Only mild side effects (a rise in slowness and
gastric discomfort) were reported. These benefits of Pycnogenol® on ADHD symptoms were
attributed to its ability to increase nitric oxide production. Nitric oxide plays a role in the
regulation of norepinephrine and dopamine release and intake [26]. Another study (random‐
ized, double-blind, placebo-controlled) also reported that Pycnogenol® administration (1 mg/
kg/day) improves attention of ADHD children, coupled with reduction of oxidative damage
to DNA and normalization of total antioxidant status [27]. The potent antioxidant properties
of Pycnogenol® are thought to be beneficial to ADHD given the presumed role of oxidative
stress in the etiology of this disorder [28]. Pycnogenol® was also shown to normalize urinary
catecholamine concentration of children with ADHD [29] and is believed to act as a vasodilator
improving cerebral blood flow to brain regions involved in ADHD [19]. Contrastingly,
Tenenbaum et al. [30] reported that Pycnogenol® failed to produce treatment effects in adults
(24–53 years old) with ADHD over a period of 3 weeks. However, it should be noted that in
this study neither Pycnogenol® nor the positive control, methylphenidate, outperformed
placebo on any ADHD rating scale [31]. In summary, Pycnogenol® is a promising botanical
alternative for the management of ADHD and its symptoms; however, more studies are
needed before it can be used as a stand-alone ADHD treatment.
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3.2.1.2. St. John’s wort (Hypericum perforatum)
St. John’s wort is best known for its antidepressant effects. It is an alternative option for treating
mild-to-moderate depression, even in children under the age of 12, with few side effects [18].
This herb was also demonstrated to have beneficial effects on other psychiatric disorders,
including major depression, bipolar depression, obsessive-compulsive disorder, social phobia,
and somatization disorder [32]. It has been suggested that the effects of St. John’s wort may be
related to its ability to inhibit the reuptake of serotonin, norepinephrine, and dopamine [33].
For this reason, the effect of St. John’s wort was tested in a preliminary study in three ADHD
patients (14–16 years old) and the result showed that St. John’s wort improved ADHD
symptoms [33]. In contrast, a much more rigorous (randomized, double-blind, placebo-
controlled) trial reported that St. John’s wort (300 mg/day) did not improve ADHD symptoms
in 54 children (aged 6–17 years old), after 8 weeks of intervention [34]. Thus, the effects of St.
John’s wort on ADHD is still unclear, necessitating further studies.
3.2.1.3. Ginkgo biloba
Ginkgo biloba is a unique species of a tree native to East Asia. The memory enhancing effects
of G. biloba has been extensively studied, and it is being utilized as an alternative treatment for
memory impairment and dementia [35]. Some studies also reported that the ginkgo has
beneficial effects on ADHD. Uebel-von Sandersleben et al. [36] reported that G. biloba (240 mg,
daily) improved core symptoms of ADHD in children, following 3–5 weeks of treatment. G.
biloba (50 mg) was also found to alleviate ADHD symptoms in children (36 kids, ages 3–17),
when administered with ginseng (200 mg), over the course of 4 weeks [37]. In this study, minor
side effects were observed (e.g., subjects became more emotional and more impulsive, more
hyperactive and more aggressive, sweating, headache, tiredness) [37]. The beneficial effects of
G. biloba on ADHD are attributed to its various activities such as (1) improvement of cerebro‐
vascular blood flow that may help reduce hyperactivity due to lack of focus, (2) reversal of 5-
HT1A and noradrenergic receptor reductions, and (3) inhibition of both MAO-A and MAO-B
in the brain [35, 37]. However, a 6-week double-blind randomized controlled trial by Salehi et
al. [35] found that G. biloba (80–120 mg/day) was less effective than methylphenidate in
managing ADHD symptoms in a sample of 50 children.
3.2.1.4. Ginseng
Ginseng has been shown to improve ADHD symptoms [37]. Ginseng, both American (Panax
quinquefolius) and Asian (Panax ginseng), is known to produce beneficial effects on the body.
Ginseng species contain a class of phytochemicals called ginsenosides, which are known as
potent antioxidants and exert neuroprotective properties [38, 39]. Ginsenosides have also been
reported to boost levels of dopamine and norepinephrine in the brain. In this sense, ginseng
may effectively alleviate symptoms of ADHD. Indeed, an observational clinical study showed
that Korean red ginseng (KRG) (Panax ginseng), given at 1,000 mg, twice a day, for 8 weeks,
improved inattentiveness in children (18 kids, ages 6–14) with ADHD [38]. In addition, a
double-blind randomized placebo-controlled trial reported that 100 mg of KRG, taken twice a
day, decreased inattention and hyperactivity scores of ADHD children (ages 6–15 years old),
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after an 8-week treatment period [39]. Side effects associated with ginseng use included
perspiration, headache, fatigue, and a degree of repulsive feeling experienced by patients due
to the unique flavor of red ginseng [38]. Thus, ginseng has the potential to be used as a
complementary and alternative therapy for ADHD, provided that its efficacy and safety issues
are resolved.
3.2.1.5. Valerian (Valeriana officinalis)
Valerian is a perineal plant that is known to have sedative and antispasmodic effects. Valerian
has been used as a treatment for insomnia, restlessness, and anxiety [12]. Its application in the
management of ADHD has also been evaluated. In a double-blind, placebo-controlled, pilot
study, it was shown that treatment with Valerian tincture for two weeks improved ADHD
symptoms in children (30 kids) aged 5–11 years old [40]. The effects of Valerian are thought to
be facilitated by the action of valerenic acid, one of its major components, on the gamma-
aminobutyric acid (GABA) A receptor. Valerian is generally safe and its use on children ages
3–12 years is approved by the European Scientific Cooperative on Phytotherapy, provided that
it is used under medical supervision [12, 18, 40]. Nevertheless, the use of valerian as an
alternative treatment for ADHD is limited by the insufficient clinical evidence supporting its
efficacy.
3.2.1.6. Ningdong
Ningdong granule (NDG) is a Chinese medicinal preparation that has been used for various
medicinal purposes for many years now. As it showed therapeutic benefits in the treatment
of Tourette syndrome [41], the effects of Ningdong were evaluated in ADHD patients.
Accordingly, Li et al. [41] performed a randomized, methylphenidate-controlled, doubled-
blinded trial, where 72 children with ADHD were given NDG (5 mg/kg/day) or methylphe‐
nidate (1 mg/kg/day) for 8 weeks. Results showed that NDG has equivalent effect to
methylphenidate in improving ADHD symptoms, but with lesser side effects. They also
reported that NDG was well tolerated by children with ADHD as revealed by blood, urine,
and stool analysis, and renal and hepatic function assessments. Interestingly, levels of
homovanillic acid, which is involved in the regulation of dopamine, in the sera increased in
the NDG group without causing any change in dopamine concentration. Thus, the authors
suggested that NDG is a promising, safe, and effective alternative therapy for ADHD.
However, more research needs to be done before NDG can be used as an alternative ADHD
treatment.
3.2.1.7. Bacopa (Bacopa monniera)
Bacopa also known as water hyssop or Brahmi is an Ayurvedic medicine that has been used
for many centuries for its positive effects on memory, learning, and concentration. Preliminary
studies have shown that Bacopa has benefits (i.e., improvement in memory and learning tasks)
in children with ADHD [12]. These findings were supported by an open-label study demon‐
strating that Bacopa extract (225 mg/day), given for a period of 6 months, significantly
alleviated the ADHD symptoms of 31 children, ages 6–12 years old [42]. The positive effects
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of Bacopa on ADHD are thought to be achieved via cholinesterase inhibition, dopamine
regulation, neuroprotective, and/or antioxidant effects [12, 42]. Bacopa was well-tolerated by
children, with only mild gastrointestinal side effects (nausea) reported [42]. Further studies
(e.g., double-blind, randomized clinical trials) are necessary to verify the efficacy of this
botanical agent as a therapy for ADHD.
3.2.2. Nutritional medicines/supplements
Studies have shown that certain vitamins and minerals may also play a role in the pathology
of ADHD. Accordingly, a multitude of vitamins, minerals, and other nutritional supplements
have been proposed as complementary and alternative treatment for ADHD [Table 2].
Supplement Methods Results Proposed mechanismof action
Safety and
efficacy Reference
Vitamin B6
and
Magnesium
⋅ Open study
⋅ 76 children (40 ADHD
children & 36 healthy
children)
⋅ All children were
given a magnesium-
vitamin B6 (Mg-B6)
regimen (6 mg/kg/d
Mg, 0.6 mg/kg/d vit-B6)
for 8 weeks.
Mg-B6 treatment
significantly
attenuated
hyperactivity and
aggressiveness.
School attention
was also improved.
Vitamin B6 facilitates
the production of the
serotonin.
Magnesium has been
shown to be a non-
specific inhibitor of
calcium channels, and
could act as NMDA
channel inhibitor. In
the same way, it could
also influence
catecholamine
signaling in the brain.
No reported side
effects
Mousain-
Bosc et al.,
(2006) [43]
Zinc
⋅ Randomized, double-
blind, parallel-group
placebo-controlled
⋅ 400 children 6-14 y/o
(n=202 zinc vs. n=198
placebo)
⋅ 150 mg zinc sulfate or
150 mg sucrose
(placebo) daily for 12
weeks
Zinc sulfate was
better than placebo
in decreasing
hyperactivity,
impulsivity and
improving
socialization, but
not inattention.
Deficiency in zinc is
suggested to play a
role in hyperactivity,
concentration
impairment and delay
of cognitive
development.
No serious side
effects reported.
However, metallic
taste was a
common
complaint.
Bilici M et
al., (2004)
[47]
⋅ Randomized, double-
blind, placebo-control
⋅ 44 children, 5-11 y/o
(n=22 methylphenidate
Significantly greater
treatment effects
were observed in
zinc sulfate with
Zinc regulates
dopamine function,
indirectly, through its
action on melatonin.
Nausea and
metallic taste
were frequent
complaints from
Akhondzad
eh et al.,
(2004) [46]
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Supplement Methods Results Proposed mechanismof action
Safety and
efficacy Reference
+zinc vs. n=22
methylphenidate
+placebo)
⋅ Methylphenidate
1mg/kg/day; 55 mg/day
zinc sulfate; sucrose
(placebo) 55 mg, for 6
weeks
methylphenidate
over placebo with
methylphenidate.
the participants.
Overall, it was
well tolerated.
⋅ Randomized, double-
blind, placebo-
controlled, pilot trial
⋅ 52 children 6-14 y/o
(n=20 Zinc_1 or n=8
Zinc_2 v. n=24 placebo)
⋅ Zinc_1 15 mg/day
(once a day) or Zinc_2
30 mg/day (twice a day)
or placebo (8 weeks);
amphetamine 5-15 mg/
daily (based on the
weight)
⋅ Duration of
experiment was 13
weeks (8 weeks
controlled + 5 weeks
amphetamine add-on)
No appreciable
difference between
both dosages of zinc
and placebo
The addition of
amphetamine to
zinc
supplementation
did not alter the
result.
Zinc is an important
cofactor in the
metabolism of relevant
to neurotransmitters,
prostaglandins, and
melatonin and
indirectly affects
dopamine metabolism.
Specific to ADHD, the
dopamine transporter
has a zinc building site
that blocks transport.
1 patient reported
gastrointestinal
discomfort.
Arnold L et
al., (2011)
[48]
Iron
⋅Randomized, double-
blind, placebo-
controlled, pilot trial
⋅ 23 children with low
serum ferritin level
( <30 ng/mL) 5-8 y/o
(n=18 iron vs. n=5
placebo)
⋅ 80 mg ferrous sulfate
tablets or placebo once
daily in the morning for
12 weeks
Iron
supplementation
significantly
improved
hyperactive/
impulsive and
inattentive
symptoms of
ADHD.
Iron is a co-factor in
the synthesis of both
norepinephrine and
dopamine. Iron
deficiency was also
strongly suggested to
correlate with ADHD
and restless leg
syndrome.
Minor side effects
were reported,
such as nausea,
constipation, and
abdominal pain.
Konofal E et
al., (2008)
[49]
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Supplement Methods Results Proposed mechanismof action
Safety and
efficacy Reference
Essential fatty
acid
supplement
⋅ Randomized, double-
blind, placebo-
controlled
⋅ Initially, 41 children
participated but were
reduced to 29 children
due to side effects, 8-12
y/o (n=15 HUFA v.
n=14 placebo)
⋅ Highly unsaturated
fatty acid (HUFA)
supplement (daily doses:
EPA 186 mg, DHA 480
mg, γ-linolenic acid 96
mg, vitamin E 60 IU,
cis-linoleic acid 864 mg,
AA 42 mg and thyme
oil 8 mg) or olive oil
(placebo), for 12 weeks
HUFA
supplementation
significantly
attenuated ADHD-
related symptoms.
HUFA can profoundly
influence signal
transduction.
A digestive upset
and difficulty of
swallowing were
the only
documented
complaints.
Ricahrdson
and Puri B.
(2002) [53]
⋅ Open-label, proof-of-
efficacy pilot study
⋅ 9 children 8-16 y/o
⋅ 16.2 g EPA/DHA
concentrates per day.
The dosage was
adjusted dependent on
the ratio of arachidonic
acid (AA) to EPA in the
isolated plasma
phospholipids at four
weeks
High dose of
EPA/DHA
supplement
improved ADHD-
related symptoms
Children with ADHD
were found to have
low levels of LC
PUFAs, including AA,
EPA and DHA in the
plasma phospholipids,
as well as high ratio of
AA to EPA.
One participant
reported of loose
stools while
taking 30 ml of
the liquid of
EPA/DHA
concentrate per
day.
Sorgi P et
al., (2007)
[52]
⋅ Randomized, double-
blind, cross-over,
placebo-controlled
⋅ 132 children (104
completers) 7-12 y/o
( n=36 PUFAs v. n= 41
PUFA + micronutrients
v. n=27 placebo)
Significant
treatment effects
were found for
parents rating of
ADHD symptoms
in both PUFA
treatment groups
compared to
placebo.
PUFAs are key
components all cellular
and intracellular
membranes or
phospholipids,
where they perform
vital structural and
chemical functions
No reported
adverse effects.
Sinn N and
Bryan J,
(2007) [55]
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Supplement Methods Results Proposed mechanismof action
Safety and
efficacy Reference
⋅ Six PUFA capsules
400 mg fish oil and 100
mg evening primrose
oil or six palm oil
(placebo) capsules a
day, for 15 weeks
Single crossover
(placebo to PUFA)
for another 15
weeks reiterated
these results.
No additional
effects from
micronutrients are
noted.
Other nutrients and
vitamins are involved
in
the PUFA role of
synthesizing
prostaglandins,
chemicals
with important
biological roles in
brain function
⋅ Randomized, one-
way cross-over,
placebo-controlled
(Phase 1 double-blind;
phase 2 single blind)
⋅ 7-12 y/o
Phase 1- 132 children
with ADHD (n= not
specified) PUFA vs.
PUFA+ multivitamins/
minerals vs. placebo,
for 15 weeks
⋅ Phase 2- 109 ADHD
children (n=not
specified) all children
were given PUFA+
multivitamins/minerals
for another 15 weeks
⋅ Six active or six
placebo capsules per
day
After 15 weeks,
improvements from
the PUFA group in
their ability to
switch and control
attention compared
to the placebo
group. Similar
observation from
the placebo group
after taking PUFA
supplement from
weeks 16-30.
No significant
improvements in
other cognitive
measures, or with
additional
micronutrient
supplementation
PUFA have been
associated with
dopamine activity in
the frontal lobes of the
brain.
Slight nausea was
reported in two
patients and one
report episodes of
nose bleeding.
Sinn N,
Bryan J, and
Wilson C,
(2008) [57]
⋅ Randomized, double-
blind, single-center,
placebo-controlled (15
weeks) (phase 1)
followed by an open-
label extension (15
weeks) (phase 2)
⋅ Phase 1- 200 children
6-13 y/o
Omega-3
supplement
significantly
attenuated
hyperactivity/
impulsivity, as well
as mood/behavior
dysregulation.
Omega3 LC-PUFA has
been linked to brain
and central nervous
system functioning,
and a deficiency in
Omega3 fatty acids in
rats and monkeys is
associated with
behavioral, sensory,
No major adverse
effects
documented apart
from
gastrointestinal
discomfort, atopic
dermatitis,
hyperactivity, tics,
nausea, elevated
Manor I et
al., (2012)
[56]
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Supplement Methods Results Proposed mechanismof action
Safety and
efficacy Reference
⋅ 2 capsules
phosphatidylserine
(PS)-Omega 3 (300 mg
of PS and 120 mg of
EPA + DHA) or 2
capsules filled with
cellulose (placebo) 2
times/day.
⋅ Phase 2 –
⋅ 150 children all
participants received
two capsules of PS-
Omega3 daily which
provided 150 mg of PS
and 60 mg of EPA +
DHA
Sustained efficacy
were noted who
continued to
received PS-Omega
3 in the open-label
extension
and neurological
dysfunction.
serum glutamic
oxaloacetic
transaminase
(SGOT) and
tantrum episodes
⋅ Randomized, double-
blind, placebo-
controlled
⋅ 78 children 7-13 y/o
(n=39 EFA supplement
v. n=39 placebo Vitamin
C.)
⋅ EFA capsule (240 mg
of linoleic acid (LA), 60
mg of a-linolenic acid
(ALA), 95 mg of
mineral oil, and 5 mg of
a-tocopherol (as an
antioxidant) 2
times/day or Vit. C (500
mg ascorbic acid) 2
times/day, for 7 weeks
Although both
interventions
ameliorated some
ADHD symptoms,
no significant
differences were
found between the
groups.
Essential fatty acids
(EFA) are needed for
normal sensory,
cognitive, and motor
function
Well tolerated
and no adverse
effects were
reported.
Raz R,
Carasso RL,
Yehuda S
(2009) [58]
⋅ Randomized, double-
blind, placebo-
controlled
⋅ 50 children 6-13 y/o
(n=25 LC-
Polyunsaturated fatty
No apparent benefit
was noted for the
PUFA
supplementation for
the ADHD
symptoms
PUFA supplement
contains DHA. DHA is
thought to reflect the
proportion of FA in the
brain, and a decrease
of the former in the
blood might mediate
Well tolerated
and no adverse
effects were
reported.
Stevens L et
al., (2003)
[54]
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Supplement Methods Results Proposed mechanismof action
Safety and
efficacy Reference
acids (PUFAs) v. n=25
placebo olive oil
⋅ 8 capsules of PUFA or
placebo a day, for 4
months
the abnormal neuronal
signaling that results
in aberrant behaviors.
⋅ Randomized, double-
blind, placebo-
controlled
⋅ 54 children 6-12 y/o
(n=27 Docosahexaenoic
acid (DHA) v. n=27
placebo)
⋅ 345 mg of DHA per
day (n=32) or a placebo
capsule (n =31) for 4
months
DHA
supplementation
did not significantly
improve in any
objective or
subjective measure
of ADHD
symptoms.
There is a direct
relationship between
plasma phospholipid
DHA content and
metabolism of
serotonin and
dopamine within the
central nervous system
DHA and other
polyunsaturated fatty
acids may influence
synaptic functions
through effects on
membrane structures.
Well tolerated
and no adverse
effects were
reported.
Voigt et al.,
(2001) [60]
⋅ Randomized, double-
blind, placebo-
controlled
⋅ 40 children with
ADHD 6-12 y/o (n=20
docosahexaenoic acid
(DHA) v. n=20 placebo)
⋅ DHA group took
fermented soybean
milk (600 mg DHA/125
ml, 3/week), bread rolls
(300 mg DHA/ 45 g, 2/
week) and steamed
bread (600 mg DHA/60
g, 2/week) or placebo
foods containing olive
oil instead of DHA-rich
fish oil for 2 weeks.
DHA
supplementation
did not improve
ADHD-related
symptoms.
Levels of DHA was
significantly lower in
the serum
phospholipid fraction
in hyperactive children
No serious side
effects were
reported in the
study.
Hirayama S,
Hamazaki T,
and
Terasawa K
(2004) [59]
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Supplement Methods Results Proposed mechanismof action
Safety and
efficacy Reference
Acetyl-L-
Carnitine
⋅ Randomized, double-
blind placebo-
controlled, parallel, and
multicenter
⋅ 51 children(ADHD
and Fragile X
syndrome) 6-13 y/o
(n=24 ALC v. n=27
placebo)
⋅ Acetyl-L-Carnitine
(20-50 mg/kg/day) 500
mg 2 times/day or
placebo for 52 weeks
Acetyl-L-Carnitine
significantly
ameliorated the
symptoms of
ADHD over placebo
on Clinical Global
Impressions (CGI)
parental rating, but
not on CGI teacher’s
rating.
Acetyl-L-Carnitine was
found to improve
learning and attenuate
the hyperactivity in a
rat model of neonatal
anoxia
Safe and tolerable
with no side
effects reported
Torrioli et
al., (2008)
[62]
⋅ Multi-site parallel-
group double-blind
randomized pilot trial
⋅ 112 children 5-12 y/o
(n=53 Acetyl-L-
Carnitine v. n=59
placebo)
⋅ ALC in weight-based
doses from 500 to 1500
mg 2 times/day or
placebo for 16 weeks
No significant
treatment effects to
overall ADHD
rating outcome.
Superiority of
Acetyl-L-Carnitine
over placebo in the
inattentive subtype
Acetyl-L-Carnitine
exerts mild M3
muscarinic receptor
agonism in rats,
simulating
acetylcholine release.
The compound
significantly increases
glutamatergic receptor
binding and protects
against age-related
reductions in the
GABA/benzodiazepine
receptor binding
capacity
Safe and tolerable
with no side
effects reported
Arnold L et
al., (2007)
[63]
Table 2. Nutritional medicines/supplements for ADHD
3.3. Vitamins
Vitamins have been considered as an adjunct or alternative treatment for ADHD, although no
studies have systemically evaluated their effects in ADHD patients. The use of vitamins for
ADHD has been based on the finding that multivitamin supplements improved concentration
and attention in children without ADHD [18]. In particular, Vitamin B6 (0.6 mg/kg/day)
combined with magnesium (6 mg/kg/day) improved clinical symptoms of children with
ADHD following an 8-week treatment period [43]. ADHD symptoms returned a few weeks
after treatment was stopped. The beneficial effect of vitamin B6 on ADHD has been attributed
to its ability to facilitate the production of the catecholamine, serotonin [12, 44]. In addition,
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despite not directly addressing ADHD symptoms, vitamin or multivitamin supplementation
can provide additional benefits for children with ADHD, who usually have poor dietary habits
[18]. Caution must be exercised, however, with the use of large doses of vitamins, existing as
megavitamins or megadoses, especially in young patients, considering the limited evidence
to support the efficacy of vitamins in improving ADHD symptoms [18]. Double-blind,
randomized, clinical studies are needed to substantiate the use of vitamins for the treatment
of ADHD.
3.4. Minerals
Mineral supplementation has also been proposed to be an alternative intervention for ADHD.
Mineral deficiencies have also been implicated in the etiology ADHD, and thus mineral
supplementation may be useful to correct the underlying mineral deficiency and possibly
control ADHD symptoms. In addition, minerals are cofactors in the synthesis, uptake, and
breakdown of important neurotransmitters, also implicated to play crucial roles in ADHD
symptomatology [19, 45].
Of the mineral supplements, zinc may have been the most studied and have received much
support as an adjunct treatment for ADHD [19]. Low levels of zinc have been associated with
deficits in several cognitive functions including information processing [19, 46]. Thus, zinc
supplementation may have beneficial effects on cognition and related processes. In a 12-week,
double-blind study, children supplemented with 150 mg of zinc sulfate showed reductions in
hyperactivity, impulsivity, and impaired socialization [47]. Akhondzadeh et al. [46] also
reported that zinc sulfate augmented the effect of methylphenidate in alleviating ADHD
symptoms in children. Zinc is generally well-tolerated with only minor side effects reported
(e.g., gastrointestinal discomforts and metallic taste). However, Arnold [48] showed negligible
clinical effects of zinc supplementation in ADHD patients. These discrepant results are
possibly due to differences in underlying nutritional status, genetic factors, and/or dosages of
zinc used in different studies [18]. More elaborate and comprehensive clinical studies are
required to solve these discrepancies.
Another mineral that has received special attention and has been evaluated in clinical trials
for ADHD treatment is iron. Previous studies showed that children with iron-deficiency
anemia also displayed attentional deficits [45]. Iron is a co-factor in the synthesis of both
norepinephrine and dopamine [11, 19]. A randomized, double-blind, placebo-controlled study
found that iron supplementation improved ADHD symptoms in children (23 kids, 5–8 years
old) [49]. However, in the absence of anemia, iron supplementation in children with ADHD
did not produce consistent behavioral improvements [19, 45].
Magnesium was also shown to improve ADHD symptoms. Magnesium is involved in
neurotransmitter synthesis, and some studies have even associated magnesium deficiencies
with ADHD [50]. Indeed, supplementation of magnesium and vitamin B6 in ADHD children
improved ADHD symptoms [43].
Altogether, these findings indicate that certain minerals may be helpful in the treatment of
ADHD. However, caution must be practiced when using minerals because of potential health
risks associated with intake of large dosages.
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3.5. Essential fatty acids
In recent years, there has been a lot of interest on the benefits of essential fatty acid (EFA,
e.g.,  omega-3,  omega-6)  supplementation in children with ADHD. EFA supplementation
exerted modest effects on alleviating the symptoms of ADHD [51, 52]. Richardson and Puri
[53] reported that high-dose supplementation of EFA (fish oil; 8–16 g) improved behavior
and inattention and reduced hyperactivity and defiance in children with ADHD. Another
report  also  indicated better  attention and behavioral  improvement  in  children receiving
combined  omega-3  and  omega-6  supplementation  [54].  Similarly,  Sinn  and  Bryan  [55]
reported  significant  improvement  in  ADHD  symptoms  (parent-rated  behavior  and
attentional tasks) in children given EFA for 15 weeks, versus the placebo-treated group. Of
note, other investigators have reported selective improvement (parent-reported benefits for
restless-hyperactive  symptoms  in  the  absence  of  teacher-reported  effects)  of  ADHD
symptoms in subjects after EFA supplementation [56, 57]. While the exact mechanism EFAs
in ADHD is not yet established, the efficacy of EFAs may be attributed to its effects on
brain development (e.g., cell growth, neural signaling, and effects on gene expression) [18,
51].  It  has also been postulated that  increased EFA levels  in cellular membranes impact
dopaminergic and serotonergic activity [19, 51].
Nevertheless, other studies have also reported no significant or very minimal effects of EFA
treatment in ADHD patients vs. placebo-treated group. A randomized clinical trial reported
that EFAs had minimal effects on ADHD symptoms [58]. Another study also did not find any
benefit of two month EFA supplementation in subjects [59]. In addition, Voigt et al. [60]
reported that four months of DHA supplementation (345 mg/day) did not decrease symptoms
of ADHD. In one study, omega-3 fatty acid supplements have even been associated with
worsening of inattention [19, 57].
In summary, although some studies have reported therapeutic benefits of EFA supplementa‐
tion, the current evidence for EFA as a complementary and alternative medicine for ADHD is
not yet established [61].
3.6. Amino acids
Amino acid supplements have also been considered as a complementary intervention for
ADHD. These include acetyl-L-carnitine (ALC), GABA, glycine, L-theanine, L-tyrosine,
taurine, 5-hydroxytryptophan (5-HTP), and s-adenosyl-L-methionine (SAMe) [12, 18].
However, research regarding amino acid supplementation for ADHD treatment in children
has produced inconsistent data. Various risks have been reported with their use and only short-
term benefits of the supplements have been found [18]. Most research in this field has focused
on supplementation with ALC, an amino acid derivative. A randomized, double-blind
placebo-controlled study reported that ALC supplementation significantly ameliorated the
symptoms of ADHD in 51 children, aged 6–13 years old [62]. However, a double-blind,
placebo-controlled clinical trial reported that ALC supplementation has no significant effect
on the overall ADHD population (112 children, 5–12 years old) [63].
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4. Emerging natural interventions for ADHD and other treatment options
4.1. Novel interventions: evidence from preclinical studies
4.1.1. Oroxylin A
Oroxylin A (5,7-dihydroxy-6-methoxyflavone) shows potential as a natural intervention for
ADHD. Oroxylin A is a flavonoid isolated from the root of Scutellaria baicalensis Georgi, a herb
commonly found in East Asia. It exerted antioxidant, anti-inflammatory, and anti-allergy
activities, and produced memory-enhancing and neuroprotective effects. Studies showed that
Oroxylin A in an antagonist of the γ-aminobutyric acid (GABA)-A receptor [64]. Preclinical
studies have shown that Oroxylin A or its derivative (5,7-dihydroxy-6-methoxy-4'-phenoxy‐
flavone) improved ADHD-like behaviors of the spontaneously hypertensive rat, an animal
model of ADHD [65, 66]. The beneficial effects of Oroxylin A are believed to be mediated via
enhancement of dopamine neurotransmission. Studies are underway to determine the efficacy
of oroxylin A in ADHD patients.
4.1.2. YY162
YY162 is pharmaceutical combination of terpenoid-strengthened G. biloba and ginsenoside Rg3
from ginseng. A recent study has shown that YY1612 attenuated ADHD-like conditions
induced by Aroclor1254 in mice [67]. It also exerted neuroprotective effects with negligible
behavioral side effects. These effects of YY162 were comparable to those produced by meth‐
ylphenidate. The positive effects of YY162 on ADHD-like behavior are believed to be mediated
through its antioxidant properties and its ability to positively modulate the dopamine and
norepinephrine transporters. Studies on the effects YY162 in patients with ADHD would be
invaluable to determine its worth as an ADHD medication.
4.2. Combination treatment and integrative approaches
Because ADHD is a multifactorial disorder, a multi-modal approach may prove effective in
managing ADHD symptoms. A recent and growing trend in the management of ADHD is the
combination of various ADHD treatment options (e.g., medication and behavioral therapies)
also referred to as combination therapy, integrative, or multi-modal approach. Multi-modal
approaches are highly recommended because it is believed to provide a more “holistic” and
patient-specific approach.
Due to that fact that stimulants are the most widely used treatment for ADHD, most multi-
modal approaches practiced or studied employed the use of a stimulant drug coupled with a
behavioral/psychosocial therapy. In a landmark randomized clinical trial known as the
Multimodal Treatment Study of Children with ADHD, it was shown that the combination
behavioral and medication interventions was superior compared to the individual effects of
its component [68]. However, this did not go uncontested because other large-scale and long-
term clinical trials have reported contradicting results [4].
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Very few studies have evaluated the effects of medication and/or behavioral therapy combined
with a nutritional/botanical component. Notably, Akhondzadeh et al. [46] performed a
randomized, double-blind, trial evaluating the effects of zinc sulfate as an adjunct to methyl‐
phenidate. The result showed that the zinc enhanced the effects of methylphenidate in children
(ages 5–11) with ADHD. This study stands as an example that natural products are very
promising when used with other ADHD treatments.
5. Conclusion
There are a number of available treatment options for ADHD, however, some of them may
pose risks to patients [18]. The botanical agents discussed in this study appear to be promising
ADHD treatments considering their therapeutic effects and negligible negative side effects. Of
the botanical agents reviewed, Pycnogenol is the most studied, widely supported, and
promising ADHD treatment. Nutritional supplements are also generally considered safe, and
among them, EFAs stand out as potential ADHD interventions. Although the use of natural
medications for ADHD has been considered as a “safer” approach, natural products are still
far from being called as standard ADHD treatments due to the lack of comprehensive and
appropriately controlled clinical studies that interrogate both their efficacy and safety. Thus,
more rigorous, appropriately designed clinical trials are required prior to establishing their
worth as ADHD drugs.
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